Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH

BOSTON & SHANGHAI–(BUSINESS WIRE)–Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MOSAIC, the company’s Phase 2a clinical trial evaluating ECC4703, ECC0509 and their combination in adults with MRI-based or clinically defined metabolic dysfunction-associated steatohepatitis (MASH). The … [Read more…]

Latent Labs Announces Latent-X2: AI-Generated Antibodies With Drug-Like Developability and Low Ex Vivo Immunogenicity

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab’s AI platform, built on Latent-X2, to access difficult targets and accelerate development timelines by reducing wet lab work. The generated designs display drug-like properties including low ex vivo immunogenicity, … [Read more…]

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline

Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of doses of 212Pb every year Partnership with the United Kingdom National Nuclear Laboratory (UKNNL) to scale up the extraction of … [Read more…]

Mitsubishi Electric Technology Detects Intoxication During Driving to Provide Driver Alerts and Even Vehicle-control Interventions

Verified for compliance with European and U.S. regulatory and assessment frameworks, aiming to help reduce traffic accidents caused by drunk driving TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a technology that accurately detects intoxication levels indicated by driver distraction and drowsiness, and provides driver alerts and vehicle-control interventions as needed … [Read more…]

Washington Launches New Tools to Help Medical Professionals Deliver Life-saving Medications for Opioid Use Disorder

The Health Care Authority (HCA) and Department of Health (DOH) are equipping health care providers and emergency medical services (EMS) personnel with practical, research-based resources to expand treatment access and reduce overdose deaths. OLYMPIA, Wash.–(BUSINESS WIRE)–The Washington State Health Care Authority (HCA) and Department of Health (DOH) just released a new resource library to help … [Read more…]

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed … [Read more…]

CVCT 2025: Cleerly Late-Breaking Science Identifies Thresholds of High Plaque Burden in Non-Obstructive CAD that May Carry Greater Risk Than Obstructive Disease

Sixth late-breaking presentation from CONFIRM2 Registry demonstrates 12-fold risk gradient based on total plaque burden DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in AI-based cardiovascular imaging, presented new, late-breaking science from the international CONFIRM2 Registry at the Global CVCT Scientific Program 2025 in Washington, DC. The study, “AI-Guided Quantification of Atherosclerosis on Coronary CT for Identification of High-Risk … [Read more…]

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

ST. LOUIS–(BUSINESS WIRE)–Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor’s nationwide expansion and broaden patient access to its immunotherapy-response diagnostics. Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 … [Read more…]

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Company reiterates fiscal 2026 guidance Company raises long-term guidance expectations to reflect OneOncology’s expected long-term contribution to enterprise growth CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform … [Read more…]

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

ATHENS, Greece–(BUSINESS WIRE)–  ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreement with Otsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., … [Read more…]